News World Gilead remdesivir results mixed in moderate COVID-19 patients

Gilead remdesivir results mixed in moderate COVID-19 patients

 

Gilead Sciences Inc said on Monday its antiviral drug remdesivir had mixed results in a late stage study of people with moderate COVID-19, as patients given a five-day course of the treatment showed statistically significant improvement, while those given it for 10-days did not.

Gilead shares fell about 2.7 percent in early trading.

Remdesivir is being closely watched after the U.S. Food and Drug Administration granted emergency use authorization last month, citing results from another study run by the National Institutes of Health that showed the drug reduced hospitalization stays by 31%, or about four days, compared to a placebo.

Remdesivir, which previously failed as a treatment for Ebola, is designed to disable the mechanism by which certain viruses, including the new coronavirus, make copies of themselves and potentially overwhelm their host’s immune system.

The results announced by Gilead on Monday are from a study designed to evaluate the safety and efficacy of 5- and 10-day treatment with remdesivir in addition to standard of care for patients with moderate COVID-19, compared with standard care alone.

At Day 11, more patients in the 5-day treatment group showed improvement in clinical status versus the standard of care group, Gilead said.

The drugmaker said the odds of improvement with the 10-day treatment course of remdesivir versus standard of care were also favorable, trending toward but not reaching statistical significance.

Jefferies analyst Michael Yee said the improvements seen in the trial patients were only modest.

“COVID-19 patients entering the hospital are likely to get the drug given there are no other major alternatives, but it is understood the drug is meant to be more helpful (and not a cure) in a moderate population, where patients are generally healthier and the mortality rate is expected to be very low,” Yee wrote in a research note.

(Reuters)

Top Stories

122 new cases, one death announced on Friday

The Health Ministry announced the death of one person due to COVID-19. This raises the death toll from the virus in Cyprus to 179,...

Where to get antigen rapid tests on Saturday

The Health Ministry announced the following antigen rapid test sites for Saturday, 23 January 2021: LIMASSOL Grigoris Afxentiou Square 08:30-16:30 Gafkos Clerides Park, Germasoyia 08:30-16:30 Municipal Hall Ypsonas...

Civil servants’ trade union requests psychological support for health professionals

PASYDY, the civil servants’ trade union requested psychological support for health professionals due to the consequences of COVID-19 on their health. The trade union noted...

Scientific advisory committee to convene on Monday under President Anastasiades

Cyprus President, Nicos Anastasiades, will preside on Monday morning over a meeting of the scientific advisory committee on COVID-19. According to CNA information, during the...

Polish medics depart for Slovakia to help mass testing

A group of 200 Polish medics departed for neighbouring Slovakia on Friday (January 22) to help in a week-long testing campaign in the central...

Taste

Squash soup

Ingredients: 1 kg pumpkin, cut into small cubes, approximately 5 cups 2 medium (400g) sweet potatoes, cut into cubes, approximately 2 ½ cups 1 chopped leek, only...

Mezedes

No visit to Cyprus is complete without enjoying the traditional meal of many small dishes known as ‘meze’. This large feast, which has been a...

Prawns with fried cheese, barley shaped pasta

Put the barley shaped pasta into a small pan with salted water, bring to a boil and when tender, drain. Peal the prawns leaving...

Salmon and shrimp sheftalies

Mix all ingredients for tabbouli in a bowl and keep to one side so flavours can combine. Prepare the sheftalies: wash and soak the casing...